|
The Company
NanoCyte Inc. was founded in November 2000 by a group of science and business professionals with an internationally established track record of success. The company is registered in the state of Delaware, USA. NanoCyte (Israel) Ltd. is a fully owned R&D subsidiary operating from Or Akiva, mid-way between Tel Aviv and Haifa.
 |
|
Our Core Business
NanoCyte has developed an immediate, active release, topical delivery platform technology. NanoCyte is utilizing marine extracted micro-injectors, providing a GMP-grade topical formulation which penetrates the skin within a fraction of a second, and actively delivers the compound into the epidermal skin layer. The micro-injectors may continue to facilitate delivery across the skin barrier for several hours in a passive form as long as they are not removed (wiped off) from the skin.
|
NanoCyte leverages its proprietary technology platform via two avenues:
- The cosmeceutical market: where time to market is short and high efficiency resulting in reduced treatment term/ active concentration is rewarded.
- The pharmaceutical market: where immediate, effective drug delivery, improved patient compliance and efficient topical delivery are highly desirable.
NanoCyte strives to partner with global leaders in the personal care and pharmaceutical fields to bring products to the market with distinct performance and quality.
|
|
|
